Capmatinib is used in the treatment of non-small cell lung cancer.
Capmatinib works by inhibiting the action of an abnormal protein that promotes the proliferation of cancer cells. This mechanism helps to slow or halt the spread of cancer cells.
Common side effects of Capmatinib include edema (swelling), nausea, musculoskeletal stiffness, breathlessness, fatigue, vomiting, cough, and decreased appetite.